{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:36:00Z","timestamp":1789940160451,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1136\/ard.2007.074229","type":"journal-article","created":{"date-parts":[[2007,7,21]],"date-time":"2007-07-21T00:34:01Z","timestamp":1184978041000},"page":"402-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":148,"title":["Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results"],"prefix":"10.1016","volume":"67","author":[{"given":"A","family":"Kavanaugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Rosengren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S J","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Hammaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G S","family":"Firestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Kalunian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D L","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.074229_bib1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2567.1999.00772.x","article-title":"Do self-perpetuating B lymphocytes drive human autoimmune disease?","volume":"97","author":"Edwards","year":"1999","journal-title":"Immunology"},{"key":"10.1136\/ard.2007.074229_bib2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1078\/0171-2985-00200","article-title":"Effective B cell depletion with rituximab in the treatment of autoimmune diseases","volume":"206","author":"Kneitz","year":"2002","journal-title":"Immunobiology"},{"key":"10.1136\/ard.2007.074229_bib3","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.10947","article-title":"Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy","volume":"48","author":"Silverman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.074229_bib4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nri1838","article-title":"B-cell targeting in rheumatoid arthritis and other autoimmune diseases","volume":"6","author":"Edwards","year":"2006","journal-title":"Nat Rev Immunology"},{"key":"10.1136\/ard.2007.074229_bib5","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/art.22020","article-title":"Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms","volume":"54","author":"Silverman","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.074229_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2007.074229_bib7","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.074229_bib8","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.074229_bib9","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.074229_bib10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"key":"10.1136\/ard.2007.074229_bib11","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating autoantibodies, and clinical relapse","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.074229_bib12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2217\/17460816.1.4.493","article-title":"B-cell depletion in rheumatoid arthritis: the prospect of long-term benefit","volume":"1","author":"Leandro","year":"2006","journal-title":"Future Rheumatol"},{"key":"10.1136\/ard.2007.074229_bib13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/art.22400","article-title":"Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis","volume":"56","author":"Vos","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.074229_bib14","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4049\/jimmunol.167.2.1072","article-title":"Lymphoid neogenesis in rheumatoid synovitis","volume":"167","author":"Takemura","year":"2001","journal-title":"J Immunol"},{"key":"10.1136\/ard.2007.074229_bib15","doi-asserted-by":"crossref","first-page":"R352","DOI":"10.1186\/ar1004","article-title":"Quantitative biomarker analysis of synovial gene expression by Q-PCR","volume":"5","author":"Boyle","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2007.074229_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0197-2456(94)90036-1","article-title":"The case for confidence intervals in controlled clinical trials","volume":"15","author":"Borenstein","year":"1994","journal-title":"Control Clin Trials"},{"key":"10.1136\/ard.2007.074229_bib17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.62.7.635","article-title":"Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis","volume":"62","author":"Smeets","year":"2003","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724218835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724218835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.074229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T15:41:27Z","timestamp":1736091687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724218835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0003496724218835"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.074229","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.074229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 2008 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}